May 2007
Worldwide Biotech;May2007, Vol. 19 Issue 5, p1
Trade Publication
This article reports on the worldwide exclusive license agreement signed by BioLineRx Ltd., a drug development company in Israel, concerning a peptide for the treatment of inflammatory diseases, with Yissum Research Development Company of the Hebrew University of Jerusalem and Ramot at Tel Aviv University Ltd. The peptide called BL-4020 can serve as an inflammatory agent in diseases like allergic asthma and colitis.


Related Articles

  • OTHER NEWS TO NOTE.  // BioWorld Today;3/22/2007, Vol. 18 Issue 56, p2 

    The article offers news briefs on the pharmaceutical industry. Two products, the AV002 intermediate-acting, non-depolarizing neuromuscular blocking compound and a reversal agent, from Cornell University were licensed by Avera Pharmaceuticals Inc. A global license agreement has been signed by...

  • Yissum & Vaxan sign agreement for development of silver nanoparticles for Conductive Inks.  // Paintindia;Feb2011, Vol. 61 Issue 2, p77 

    The article reports on a licensing and research agreement signed by Yissum Research Development Co. Ltd. and Korea-based Vaxan Steel Co. Ltd. to develop silver nanoparticles and silver-coated copper nanoparticles for conductive inks. The inks invented by Shlomo Magdassi, Alexander Kamyshny and...

  • Other News To Note.  // BioWorld Today;6/28/2011, Vol. 22 Issue 124, p6 

    This section offers news briefs on the biotechnology industry as of June 28, 2011. Acorda Therapeutics Inc. is planning to transfer its headquarters to Ardsley, New York. A worldwide, exclusive license agreement has been signed by BioLineRx Ltd. with Yissum Research Development Co. Ltd. The U.S....

  • Safety study positive for cervical collar.  // Medical Device Daily;8/14/2007, Vol. 11 Issue 154, p10 

    The article reports that the Lubo Cervical Collar designed for use in trauma situations has demonstrated positive results in a safety study, according to Hadasit and Ramot at Tel Aviv University Ltd. The study was approved by the Institutional Review Board and was registered with the National...

  • Yissum Introduces a Novel Method for Treating Cancer Based on a Protein Encoded by HIV-1.  // Biomedical Market Newsletter;7/19/2012, Vol. 21, p1 

    The article provides information on a novel method for treating cancer based on Vif, a protein isolated from the Human Immunodeficiency Virus (HIV-1) by Yissum Research Development Co. Ltd. The scientists discovered a small peptide derived from the HIV-1 Vif protein, which inhibits DNA repair...

  • Licensing agreement on pain treatment.  // Medical Device Daily;5/29/2009, Vol. 13 Issue 102, p2 

    The article reports on a licensing agreement between Z-Cube and Yissum Research Development, the technology transfer company of the Hebrew University of Jerusalem. Under the agreement, the latter will create and commercialize a nanotechnology drug-delivery system for pain invented by Elka...

  • Removal Authority.  // Dispute Resolution Journal;Feb-Apr2011, Vol. 66 Issue 1, p90 

    The article discusses a court case over medical licensing rights dispute between appellant Infuturia Global Ltd. of the British Virgin Islands and Yissum Research and Development Co. of Israel. Infuturia has brought a case against Sequus Pharmaceuticals Inc. of California, Hebrew University of...

  • Agreements/contracts.  // Medical Device Daily;6/17/2009, Vol. 13 Issue 115, p3 

    The article reports on a license and development agreement signed by Nuvo Research with Mallinckrodt in 2009 involving its topical non-steroidal anti-inflammatory drug candidates, Pennsaid and Pennsaid Plus. Under the terms of the agreement, Nuvo will receive an up-front, non-refundable payment...

  • Isis, Kite Pharma Rocket Higher On Deals. AMY REEVES // Investors Business Daily;1/6/2015, pB06 

    Biotech Isis Pharmaceuticals leapt 10% to a new high above 68 Monday after it signed a licensing deal with Johnson & Johnson worth up to $835 million.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics